Literature DB >> 31100024

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients.

Marcelino Bermudez-Lopez1, Carles Forne2,3, Nuria Amigo4, Milica Bozic1, David Arroyo1,5, Teresa Bretones6, Nuria Alonso7,8, Serafi Cambray1, Maria Dolores Del Pino9, Didac Mauricio1,8,10, Jose Luis Gorriz11, Elvira Fernandez1, Jose Manuel Valdivielso1.   

Abstract

Background: Chronic kidney disease (CKD) is an independent risk factor for atherosclerotic disease. We hypothesized that CKD promotes a proatherogenic lipid profile modifying lipoprotein composition and particle number.
Methods: Cross-sectional study in 395 non-diabetic individuals (209 CKD patients and 186 controls) without statin therapy. Conventional lipid determinations were combined with advanced lipoprotein profiling by nuclear magnetic resonance, and their discrimination ability was assessed by machine learning.
Results: CKD patients showed an increase of very-low-density (VLDL) particles and a reduction of LDL particle size. Cholesterol and triglyceride content of VLDLs and intermediate-density (IDL) particles increased. However, low-density (LDL) and high-density (HDL) lipoproteins gained triglycerides and lost cholesterol. Total-Cholesterol, HDL-Cholesterol, LDL-Cholesterol, non-HDL-Cholesterol and Proprotein convertase subtilisin-kexin type (PCSK9) were negatively associated with CKD stages, whereas triglycerides, lipoprotein(a), remnant cholesterol, and the PCSK9/LDL-Cholesterol ratio were positively associated. PCSK9 was positively associated with total-Cholesterol, LDL-Cholesterol, LDL-triglycerides, LDL particle number, IDL-Cholesterol, and remnant cholesterol. Machine learning analysis by random forest revealed that new parameters have a higher discrimination ability to classify patients into the CKD group, compared to traditional parameters alone: area under the ROC curve (95% CI), .789 (.711, .853) vs .687 (.611, .755). Conclusions: non-diabetic CKD patients have a hidden proatherogenic lipoprotein profile.

Entities:  

Keywords:  Atherosclerosis; Lp(a); PCSK9; chronic kidney disease; dyslipidemia; lipoprotein subfractions

Year:  2019        PMID: 31100024     DOI: 10.1080/14728222.2019.1620206

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  11 in total

Review 1.  Atherosclerotic-nephropathy: an updated narrative review.

Authors:  Mariadelina Simeoni; Silvio Borrelli; Carlo Garofalo; Giorgio Fuiano; Ciro Esposito; Alessandro Comi; Michele Provenzano
Journal:  J Nephrol       Date:  2020-04-08       Impact factor: 3.902

2.  Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.

Authors:  Pijun Yan; Yong Xu; Ying Miao; Xue Bai; Yuru Wu; Qian Tang; Zhihong Zhang; Jiong Yang; Qin Wan
Journal:  Acta Diabetol       Date:  2021-06-28       Impact factor: 4.280

3.  Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant polycystic kidney disease.

Authors:  Vicente Pallares-Carratalá; José Manuel Valdivielso; José Luis Gorriz; David Arroyo; Luis D'Marco; Roser Torra; Patricia Tomás; María Jesús Puchades; Nayara Panizo; Jonay Pantoja; Marco Montomoli; José Luis Llisterri
Journal:  BMC Nephrol       Date:  2021-03-25       Impact factor: 2.388

4.  Triglycerides-glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease.

Authors:  Borja Quiroga; Patricia Muñoz Ramos; Ana Sánchez Horrillo; Alberto Ortiz; José Manuel Valdivieso; Juan Jesús Carrero
Journal:  Clin Kidney J       Date:  2022-03-10

5.  The association of remnant cholesterol (RC) and interaction between RC and diabetes on the subsequent risk of hypertension.

Authors:  Jie Wang; Qi Sun; Yu An; Jia Liu; Song Leng; Guang Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-25       Impact factor: 6.055

Review 6.  Computational Models Used to Predict Cardiovascular Complications in Chronic Kidney Disease Patients: A Systematic Review.

Authors:  Alexandru Burlacu; Adrian Iftene; Iolanda Valentina Popa; Radu Crisan-Dabija; Crischentian Brinza; Adrian Covic
Journal:  Medicina (Kaunas)       Date:  2021-05-27       Impact factor: 2.430

Review 7.  Role of Artificial Intelligence in Kidney Disease.

Authors:  Qiongjing Yuan; Haixia Zhang; Tianci Deng; Shumei Tang; Xiangning Yuan; Wenbin Tang; Yanyun Xie; Huipeng Ge; Xiufen Wang; Qiaoling Zhou; Xiangcheng Xiao
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

8.  Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients.

Authors:  Evangelia Dounousi; Constantinos Tellis; Paraskevi Pavlakou; Anila Duni; Vasillios Liakopoulos; Patrick B Mark; Aikaterini Papagianni; Alexandros D Tselepis
Journal:  Oxid Med Cell Longev       Date:  2021-07-20       Impact factor: 7.310

9.  Advanced lipoprotein parameters could better explain atheromatosis in non-diabetic chronic kidney disease patients.

Authors:  Marcelino Bermudez-Lopez; Hector Perpiñan; Nuria Amigo; Eva Castro; Nuria Alonso; Didac Mauricio; Elvira Fernandez; Jose M Valdivielso
Journal:  Clin Kidney J       Date:  2021-07-06

Review 10.  High-Fat Diet-Induced Renal Proximal Tubular Inflammatory Injury: Emerging Risk Factor of Chronic Kidney Disease.

Authors:  Shuxian Chen; Jinxia Chen; Shangmei Li; Fengbiao Guo; Aifen Li; Han Wu; Jiaxuan Chen; Quanren Pan; Shuzhen Liao; Hua-Feng Liu; Qingjun Pan
Journal:  Front Physiol       Date:  2021-12-07       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.